July 29, 2024 – Rockville, Md. – Psomagen is excited to announce the incorporation of Parse Biosciences combinatorial barcoding as a recent addition to our single cell offerings. Parse’s protocol uses a unique, plate based approach for highly multiplexed cell capture, supplementing Psomagen’s current single cell portfolio.
“Single-cell sequencing projects are not created equal,” says Psomagen’s Single-Cell & Transcriptomics Product Manager Linda Orzolek. “Whether it’s your sample type and size, your targets, or your research question, many factors determine what technology is right for your project. Adding more platforms to our portfolio is an important way to ensure our customers have access to the technology that most closely generates the results they’re trying to achieve.”
Parse offers three varieties of Evercode kits, able to scale to the size and number of your samples. They can accept between 12 and 96 samples per run, and a plate of these samples can support between 10,000 and 1 million cells.
| Parse Evercode WT Mini | Parse Evercode WT | Parse Evercode WT Mega | |
| Max. samples per run | 12 | 48 | 96 |
| Max. cells per sample | 833 |
2,083 | 10,417 |
| Max. cells per plate | 10,000 | 100,000 | 1,000,000 |
Key benefits of Parse technology include:
-
Fixing and permeabilizing cells. This process allows for long-term storage (up to 6 months), and is a good choice for longitudinal studies or studies in which samples can't be collected all at one time.
-
Combinatorial barcoding technology. This makes it possible to detect low expression genes.
-
Instrument-free workflow. Parse experiments can be conducted with only standard lab equipment, enabling single cell capture of larger cells.
Parse supports projects investigating:
-
3' gene expression. Identify cell types and cell trajectories in your sample with standard gene expression capture.
-
VDJ enrichment. Investigate mouse or human T cell and B cell populations isolated from a larger sample. Ideal for immunology research.
-
CRISPR screening. For analyzing complex phenotypes, identifying factors impacting treatment outcomes, and validating drug targets. This scalable option offers sensitive guide RNA detection and makes it possible to conduct CRISPR screens on small libraries that previously wouldn’t have been feasible.
-
Targeted gene capture. For when you have a specific region of the genome or transcriptome in mind, targeted gene panels allow you to get answers with less sequencing.
Other recent additions to Psomagen’s single-cell capabilities include the LeviCell EOS from LevitasBio. This system provides a gentle purification workflow prior to single-cell sequencing. This step is ideal for removing dead cells following cryopreservation, removing debris during nuclei isolation, and removing ambient RNA or other unwanted signal from a cell suspension. Cleaner samples yield cleaner data and less wasted sequencing costs.
“Sample quality is paramount to generating high quality, reproducible data,” says Linda Orzolek. “Psomagen recognizes the importance of offering a variety of options for our clients to ensure we meet their needs and the needs of their samples. If you come to us with a problem or a goal, we want to have not just a solution, but the RIGHT solution for your specific research, and that means expanding our services across multiple platforms and offering clients the flexibility that they need.”
About Psomagen
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
Contact
Linda Orzolek
Single-Cell & Transcriptomics Product Manager
About Parse Biosciences
Parse Biosciences is a global life sciences company working to develop new capabilities in human health and scientific research. With the help of Parse single-cell technology, science has made breakthroughs in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Learn more at parsebiosciences.com.
